ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AIM AIM ImmunoTech Inc

0.1279
0.00 (0.00%)
28 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AIM ImmunoTech Inc AMEX:AIM AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1279 0.1304 0.1201 0.1304 414,706 23:34:05

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

27/09/2024 1:00pm

GlobeNewswire Inc.


AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart


From Mar 2024 to Mar 2025

Click Here for more AIM ImmunoTech Charts.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will participate in a Virtual Investor CEO Connect segment on Wednesday, October 2, 2024 at 4:00 PM ET.

As part of the event, Mr. Equels will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event by emailing AIM@jtcir.com. Mr. Equels will answer as many questions as possible in the time allowed.

A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

1 Year AIM ImmunoTech Chart

1 Year AIM ImmunoTech Chart

1 Month AIM ImmunoTech Chart

1 Month AIM ImmunoTech Chart